Drug-device combination assembly: inserting fragile prefilled glass syringes into autoinjectors/pens
Much of J&J's Innovative Medicine growth (e.g. subcutaneous biologics such as Tremfya and Darzalex SC) ships as drug-device combination products, where a filled glass prefilled syringe must be assembled into an autoinjector or pen. The task involves de-nesting and handling thin-walled filled glass syringes, inserting them into a device housing, and snap-fitting caps, springs, and needle shields. Objects are fragile, the drug payload is high-value, and the process runs under aseptic/GMP controls. It is hard because grip force on glass must be modulated to avoid chipping or hairline cracks, and snap-fit engagement must be confirmed without crushing the assembly. Note that high-speed dedicated automation already serves much of this step industry-wide, so AGD's flexible-dexterity value is most relevant for higher-mix or fragile presentations; demand is inferred from J&J's large and growing combination-product portfolio rather than a specific automation announcement. We identified this through our own research; we have not confirmed the specifics with the customer directly. This page is our researched read — a starting point for that conversation.
What the task is
RESEARCHED · our reconstructionMuch of J&J's Innovative Medicine growth (e.g. subcutaneous biologics such as Tremfya and Darzalex SC) ships as drug-device combination products, where a filled glass prefilled syringe must be assembled into an autoinjector or pen. The task involves de-nesting and handling thin-walled filled glass syringes, inserting them into a device housing, and snap-fitting caps, springs, and needle shields. Objects are fragile, the drug payload is high-value, and the process runs under aseptic/GMP controls. It is hard because grip force on glass must be modulated to avoid chipping or hairline cracks, and snap-fit engagement must be confirmed without crushing the assembly. Note that high-speed dedicated automation already serves much of this step industry-wide, so AGD's flexible-dexterity value is most relevant for higher-mix or fragile presentations; demand is inferred from J&J's large and growing combination-product portfolio rather than a specific automation announcement.
Is this the actual task and sequence? What are the real tolerances, cycle rate, and reject criteria, and which steps are today's manual bottleneck? Answering these is what turns this from a researched signal into a validated use case.